Summit Therapeutics' Ivonescimab Outperforms Keytruda in China Lung Cancer Trial, Shares Triple
TL;DR Summary
Summit Therapeutics' Phase 3 HARMONi-2 study in China showed that their lung cancer therapy ivonescimab significantly improved progression-free survival compared to Merck's Keytruda in patients with advanced non-small cell lung cancer. Despite this positive result, Summit's stock saw a decline after a significant rise the previous day.
- Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study Yahoo Finance
- Pharma Billionaire's Fortune More Than Doubles In A Day On Cancer Drug Trial News Forbes
- Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy Yahoo Finance
- Summit, Akeso's antibody triumphs over Keytruda in China lung cancer trial, sending shares skyrocketing FiercePharma
- Summit Therapeutics Shares Triple After Drug Candidate Data Morningstar
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 2 min read
Condensed
83%
282 → 47 words
Want the full story? Read the original article
Read on Yahoo Finance